Go to Health Care Provider version
| Diagnosis | ALL, B-cell acute lymphoblastic leukemia | Study Status | Closed to enrollment |
| Phase | II |
| Age | Child, Adult - (2 years to 21 years) | Randomisation | N/A |
| Line of treatment | First line treatment |
| Routes of Treatment Administration | Ruxolitinib - oral; Other drugs are given as usually administered for leukemia therapy |
| Last Posted Update | 2023-11-09 |
| ClinicalTrials.gov # | NCT02723994 |
International Sponsor
Incyte CorporationPrincipal Investigators for Canadian Sites
BC Children's Hospital – Dr. David Dix
Montreal Children's Hospital – Dr. Sharon Abish
Alberta Children's Hospital – Dr. Victor Lewis
The Hospital for Sick Children – Dr. Ute Bartels
Hamilton Health Sciences Centre, McMaster University - Dr. Carol Portwine
CHU Ste Justine - Dr. Thai Tran
Centres
Medical contact
Rebecca Deyell
Social worker/patient navigator contact
Ilana Katz
Clinical research contact
Hem/Onc/BMT Clinical Trials Unit
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Medical contact
Dr. Victor Lewis
Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Dr. Carol Portwine
Social worker/patient navigator contact
Jane Cassano
Clinical research contact
Sabrina Millson
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
Social worker/patient navigator contact
Marie-Claude Charrette
Clinical research contact
Marie Saint-Jacques
Study Description
Philadelphia-like leukemia has specific genetic changes. This study is to assess the dose and effectiveness of an oral medication called ruxolitinib that targets Philadelphia-like leukemia cells. It blocks a protein called JAK. The medication is given in addition to standard therapy for the leukemia.
Based on the leukemia genetics and initial response to treatment, patients are divided into 4 groups.
Inclusion Criteria
- Patients between 1 and 21 years of age
- New diagnosis of Philadelphia-like, high-risk B-cell acute lymphoblastic leukemia
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
